(Q37113071)

English

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.

scientific article published on 17 March 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. (English)

1 reference

Europe PubMed Central

18 August 2017

phase II clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

M Borner

1

1 reference

Europe PubMed Central

18 August 2017

D Koeberle

2

1 reference

Europe PubMed Central

18 August 2017

R Von Moos

3

1 reference

Europe PubMed Central

18 August 2017

P Saletti

4

1 reference

Europe PubMed Central

18 August 2017

D Rauch

5

1 reference

Europe PubMed Central

18 August 2017

V Hess

6

1 reference

Europe PubMed Central

18 August 2017

A Trojan

7

1 reference

Europe PubMed Central

18 August 2017

D Helbling

8

1 reference

Europe PubMed Central

18 August 2017

B Pestalozzi

9

1 reference

Europe PubMed Central

18 August 2017

C Caspar

10

1 reference

Europe PubMed Central

18 August 2017

T Ruhstaller

11

1 reference

Europe PubMed Central

18 August 2017

A Roth

12

1 reference

Europe PubMed Central

18 August 2017

A Kappeler

13

1 reference

Europe PubMed Central

18 August 2017

D Dietrich

14

1 reference

Europe PubMed Central

18 August 2017

D Lanz

15

1 reference

Europe PubMed Central

18 August 2017

W Mingrone

16

1 reference

Europe PubMed Central

18 August 2017

Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland

17

1 reference

Europe PubMed Central

18 August 2017

publication date

17 March 2008

1 reference

Europe PubMed Central

18 August 2017

Annals of Oncology

1 reference

Europe PubMed Central

18 August 2017

19

1 reference

Europe PubMed Central

18 August 2017

1288-1292

1 reference

Europe PubMed Central

18 August 2017

7

1 reference

Europe PubMed Central

18 August 2017

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

Epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

Small proportions: what to report for confidence intervals?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN058

21 January 2018

Identifiers

10.1093/ANNONC/MDN058

1 reference

Europe PubMed Central

18 August 2017

release_6oqx6iu46fbonez6cnt4x7nqcu

1 reference

https://api.fatcat.wiki/v0/release/6oqx6iu46fbonez6cnt4x7nqcu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37113071&oldid=2101395758"